MissionIR News - Vical Announces Appointment of Mammen P. Mammen, Jr., M.D., to Vice President of Clinical Vaccines
Offers experience in the areas of clinical medicine, infectious disease research, medical diplomacy, clinical trials, vaccine program management, and public health
Atlanta, Georgia (PRWEB) November 04, 2012
MissionIR would like to highlight Vical, Inc., a publicly traded company that researches and develops biopharmaceutical products based on their patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company's active independent and partnered development programs include infectious disease vaccines for use in high-risk populations, infectious disease vaccines for general pediatric, adolescent and adult populations, cancer vaccines or immunotherapies, and gene-based delivery of angiogenic growth factors for treatment of cardiovascular diseases.
In the company's news last week,
Vical Inc. announced that Mammen P. “Anza” Mammen, Jr., M.D., has been appointed to the position of Vice President of Clincal Vaccines. Dr. Mammen is coming off of a 21-year career in the Army's Medical Corps, retiring as a colonel and recipient of the Legion of Merit. Throughout his career, Dr. Mammen has gained experience in the areas of clinical medicine, infectious disease research, medical diplomacy, clinical trials, vaccine program management, and public health.
“Anza brings a wealth of infectious disease vaccine knowledge to Vical's management team, including extensive experience in infectious disease research and vaccine trials,” said Vijay B. Samant, Vical's President and Chief Executive Officer. “His demonstrated expertise in clinical program management supplements Vical's existing strengths and provides focused support for our pipeline of vaccine development programs.”
In his most recent position, he worked as Infectious Disease Consultant and Chief, Pandemic Warning Team, U.S. Department of Defense, Fort Detrick, Maryland. From 2006 to 2010, he worked on vaccines in Advanced Development against dengue, hepatitis E, and HIV viruses as a Product Manager for the U.S. Army Medical Research and Material Command (USAMRMC), Fort Detrick, Maryland. While serving as Chief, Department of Virology, the Armed Forces Research Institute of Medical Sciences (AFRIMS), Thailand, from 2001 to 2006, Dr. Mammen contributed to a great array of the Army's U.S. Food and Drug Administration regulated vaccine studies. He also worked as the Principal Investigator of an infant trial to determine the safety and immunogenicity of the Army's live-attenuated dengue vaccine in Thailand, in collaboration with GlaxoSmithKline Biologicals (GSK). This particular study was published in the American Journal of Tropical Medicine and Hygiene. Another position Dr. Mammen previously held was Project Director for an efficacy trial in Nepal of a recombinant hepatitis E vaccine, conducted in collaboration with GSK, published in The New England Journal of Medicine. Other previous assignments he has held include Infectious Disease Officer, Department of Virus Diseases, the Walter Reed Army Institute of Research (WRAIR), and Chief, Internal Medicine Clinic, 121st General Hospital, Seoul, South Korea.
Dr. Mammen received his M.D. degree from the Pennsylvania State University College of Medicine and is Board-certified in Infectious Diseases. He has been elected as Fellow by the Infectious Disease Society of America (IDSA) and the American College of Physicians (ACP). He received his Internal Medicine and Infectious Disease clinical training from the Walter Reed Army Medical Center and audited the Medical Research Fellowship at WRAIR. He earned a B.A. degree in mathematics from Williams College. Dr. Mammen has authored or co-authored nearly 50 scientific publications spanning multiple emerging and re-emerging infectious diseases.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/11/prweb10091758.htmAdvertisement